...al. Nat. Commun.; published online Oct. 1, 2020doi:10.1038/s41467-020-18708-xCONTACT: Patrick Ryan Potts, St. Jude Children’s Research Hospital, Memphis, Tenn.email: ryan.potts@stjude.org
Claire Quang
St. Jude Children's Research Hospital
Cancer
Neuroendocrine...
...cytometry technology enables multiplexed detection of over 50 surface and intracellular markers from single cells.
BioCentury Staff
St. Jude Children's Research Hospital
Blue...
...were thus less responsive to immunotherapies such as checkpoint inhibitors or neoantigen-based T cell therapies. St. Jude Children's Research Hospital... ...to neoantigens is more likely to target a greater proportion of the mutations." Paul Thomas, St. Jude Children's Research Hospital... ...6; HLA - Human leukocyte antigen; RUNX1 (AML1) - Runt-related transcription factor 1
Inhua Muijrers-Chen, Associate Editor
St. Jude Children's Research Hospital
ETS...
...to develop and commercialize the ex vivo lentiviral gene therapy, which it calls MB-107, from St. Jude Children's Research Hospital... ...trading. Mustang was off $0.15 to $2.66 on Wednesday.
Brian Moy, Assistant Editor
LVXSCID gene therapy
Mustang Bio Inc.
St. Jude Children's Research Hospital...
...Tessa Therapeutics Pte. Ltd. (Singapore) and St. Jude Children's Research Hospital partnered to develop CAR-expressing virus-specific T cells to treat... ...company. Tessa Therapeutics Pte. Ltd., Singapore St. Jude Children's Research Hospital, Memphis, Tenn. Business: Cancer
Mary Romeo
Epstein-Barr Virus-Specific T Cells (EBVST)
St. Jude Children's Research Hospital
Tessa...
...commercialize an ex vivo lentiviral gene therapy to treat X-linked severe combined immunodeficiency (SCID) from St. Jude Children's Research Hospital... ...St. Jude Children's Research Hospital, Memphis, Tenn. Mustang Bio Inc. (NASDAQ:MBIO), New York, N.Y. Business: Gene/Cell therapy
Sandi Wong
Mustang Bio Inc.
St. Jude Children's Research Hospital
Interleukin-2...
...al. Nat. Commun.; published online Oct. 1, 2020doi:10.1038/s41467-020-18708-xCONTACT: Patrick Ryan Potts, St. Jude Children’s Research Hospital, Memphis, Tenn.email: ryan.potts@stjude.org
Claire Quang
St. Jude Children's Research Hospital
Cancer
Neuroendocrine...
...cytometry technology enables multiplexed detection of over 50 surface and intracellular markers from single cells.
BioCentury Staff
St. Jude Children's Research Hospital
Blue...
...were thus less responsive to immunotherapies such as checkpoint inhibitors or neoantigen-based T cell therapies. St. Jude Children's Research Hospital... ...to neoantigens is more likely to target a greater proportion of the mutations." Paul Thomas, St. Jude Children's Research Hospital... ...6; HLA - Human leukocyte antigen; RUNX1 (AML1) - Runt-related transcription factor 1
Inhua Muijrers-Chen, Associate Editor
St. Jude Children's Research Hospital
ETS...
...to develop and commercialize the ex vivo lentiviral gene therapy, which it calls MB-107, from St. Jude Children's Research Hospital... ...trading. Mustang was off $0.15 to $2.66 on Wednesday.
Brian Moy, Assistant Editor
LVXSCID gene therapy
Mustang Bio Inc.
St. Jude Children's Research Hospital...
...Tessa Therapeutics Pte. Ltd. (Singapore) and St. Jude Children's Research Hospital partnered to develop CAR-expressing virus-specific T cells to treat... ...company. Tessa Therapeutics Pte. Ltd., Singapore St. Jude Children's Research Hospital, Memphis, Tenn. Business: Cancer
Mary Romeo
Epstein-Barr Virus-Specific T Cells (EBVST)
St. Jude Children's Research Hospital
Tessa...
...commercialize an ex vivo lentiviral gene therapy to treat X-linked severe combined immunodeficiency (SCID) from St. Jude Children's Research Hospital... ...St. Jude Children's Research Hospital, Memphis, Tenn. Mustang Bio Inc. (NASDAQ:MBIO), New York, N.Y. Business: Gene/Cell therapy
Sandi Wong
Mustang Bio Inc.
St. Jude Children's Research Hospital
Interleukin-2...